EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Enhanced immunity effect of Korean Red Ginseng capsule: A randomized, double-blind and placebo-controlled clinical trial

Yi Yang, Jing Li, Shengyuan Zhou, Daoyan Ni, Cailing Yang, Xu Zhang, Jian Tan, Jingrui Yan, Na Wang

Journal of Ginseng Research · 2024-09 · 48 (5) · 504-510

DOI: 10.1016/j.jgr.2024.05.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ginseng Research, 2024-09. Verfasst von Yi Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Research Center, Conbio Technology Group Co., Ltd., Tianjin, China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korean Society of Ginseng.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As a physiological function of body, immunity can maintain health by identifying itself and excluding others. With economic development and increasingly fierce social competition, the number of sub-healthy population is gradually increasing, and the most basic problem exposed is human hypoimmunity. Hypoimmunity can be manifested as often feeling tired, catching colds, mental depression, etc. In order to enhance immunity, eating healthy foods with the effect of enhancing immunity may become an effective choice. KRG has pharmacological effects of enhancing immunity. Because the screening and evaluation method of immune population are not unified, there are relatively few KRG immunity tests for sub-health population. It is of great significance to study the effect of KRG on people with hypoimmunity to improve sub-health status.

Methods

This was a 180-day, randomized, double-blind, placebo-controlled clinical trial. According to the trial scheme design, 119 qualified subjects were included and randomly divided into the test group taking KRG and the placebo control group. Subjects need to check safety indicators (blood pressure and heart rate, blood routine, liver and kidney function, urine routine and stool routine) and efficacy indicators (main and secondary) inspection at baseline, efficacy indicators inspection during the mid-term of the test (90th days of administration), safety and efficacy indicators inspection after the test (180th days of administration).

Results

After the test, the safety indicators of placebo control group and KRG test group were basically within the normal range, and there is no significant difference in fireness score between the two groups. Through follow-up interviews, it was found that the subjects in the test group and the control group had no adverse reactions and allergic reactions such as nausea, flatulence, diarrhea, and abdominal pain during the test period. Self-comparison of the test group, the results of the main efficacy indicators: (1) immune related health scores were significantly improved in the mid-term and after the test (P < 0.01), (2) CD3 and CD4/CD8 increased significantly after the test (P < 0.05), (3) IgG, IgA, IgM and WBC increased significantly in the mid-term and after the test (P < 0.01); the results of the secondary efficacy indicators: (1) TNF-α decreased significantly in the mid-term (P < 0.05), IFN-γ decreased significantly in the mid-term (P < 0.01), (2) NK increased significantly in the mid-term and after the test (P < 0.05), (3) monocyte increased significantly in the mid-term and after the test (P < 0.01). Inter-group comparison of the test group and the control group, the results of the main efficacy indicators: (1) immune related health scores were higher than that of the control group in the mid-term and after the test (P < 0.01), (2) IgA of the test group was higher than that of the control group in the mid-term and after the test (P < 0.05); the results of the secondary efficacy indicators: (1) WBC of the test group was higher than that of the control group in the mid-term (P < 0.05); (2) monocytes of the test group were higher than that of the control group in the mid-term and after the test (P < 0.05), neutrophils of the test group were higher than that of the control group in the mid-term (P < 0.05).

Conclusion

Taking KRG has no adverse effects on the health of the subjects. According to the standard of clinical trial scheme, the immune related health scores and IgA in the main efficacy indicators were positive, which shows that KRG is helpful in enhancing human immunity.

Schlagwörter

Stichwörter der Autor:innen

Enhance immunityImmunoglobulinsKorean Red GinsengMonocytes

Autor:innen und Institutionen

  • Scientific Research Center, Conbio Technology Group Co., Ltd., Tianjin, China.
  • Laboratory Department, Tianjin Third Central Hospital, Tianjin, China.
  • Preventive Treatment of Disease Center, The Second Affiliated Hospital of Tianjin University of TCM, Tianjin, China.
  • Toxicology and Efficacy Evaluation Center, CAIQTEST (Beijing) Co., Ltd, Beijing, China.

Förderung

  • Korean Society of Ginseng

Zitieren

APA

Yang, Y., Li, J., Zhou, S., Ni, D., Yang, C., Zhang, X., Tan, J., Yan, J., & Wang, N. (2024). Enhanced immunity effect of Korean Red Ginseng capsule: A randomized, double-blind and placebo-controlled clinical trial. Journal of Ginseng Research, 48(5), 504-510. https://doi.org/10.1016/j.jgr.2024.05.007

Vancouver

Yang Y, Li J, Zhou S, Ni D, Yang C, Zhang X, et al. Enhanced immunity effect of Korean Red Ginseng capsule: A randomized, double-blind and placebo-controlled clinical trial. Journal of Ginseng Research. 2024;48(5):504-510. doi:10.1016/j.jgr.2024.05.007

BibTeX
@article{Yang2024,
  author = {Yang, Yi and Li, Jing and Zhou, Shengyuan and Ni, Daoyan and Yang, Cailing and Zhang, Xu and Tan, Jian and Yan, Jingrui and Wang, Na},
  title = {Enhanced immunity effect of Korean Red Ginseng capsule: A randomized, double-blind and placebo-controlled clinical trial},
  journal = {Journal of Ginseng Research},
  year = {2024},
  volume = {48},
  number = {5},
  pages = {504--510},
  doi = {10.1016/j.jgr.2024.05.007}
}
Kostenlos starten →